Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide

Journal of Immunology

Volumn 183, Issue 7, 2009, Pages 4346-4359

  Pozo, David ^a   Anderson, Per ^b   Gonzalez Rey, Elena ^b,c  

^a CABIMER Andalusian Center for Molecular Biology and Regenerative Medicine CSIC University of Seville UPO   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYTOKINE; PROTEIN P27; TRANSCRIPTION FACTOR FOXP3; VASOACTIVE INTESTINAL POLYPEPTIDE; EPITOPE; GROWTH INHIBITOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HLA SYSTEM; IN VITRO STUDY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN SYNTHESIS; REGULATORY T LYMPHOCYTE; STIMULATION; ACUTE DISEASE; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CLONAL ANERGY; CYTOLOGY; DISEASE MODEL; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; TRANSGENIC MOUSE; TRANSPLANTATION;

ACUTE DISEASE; ANIMALS; BONE MARROW TRANSPLANTATION; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; CLONAL ANERGY; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EPITOPES, T-LYMPHOCYTE; GRAFT VS HOST DISEASE; GROWTH INHIBITORS; HUMANS; ISOANTIGENS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES, REGULATORY; VASOACTIVE INTESTINAL PEPTIDE;

EID: 70449707793     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900400     Document Type: Article

References (62)

1. Brent, L., I. R. Cohen, P. C. Doherty, M. Feldmann, P. Matzinger, L. Ghost, S. T. Holgate, P. Lachmann, N. A. Mitchison, G. Nossal, et al. 2007. Crystal-ball gazing: the future of immunological research viewed from the cutting edge. Clin. Exp. Immunol. 147: 1-10.
2. Mills, K. H. 2004. Regulatory T cells: friend or foe in immunity to infection? Nat. Rev. Immunol. 4: 841-855.
3. Bluestone, J. A. 2005. Regulatory T-cell therapy: is it ready for the clinic? Nat. Rev. Immunol. 5: 343-349.
4. Quintana, F. J., and I. R. Cohen. 2008. Regulatory T cells and immune computation. Eur. J. Immunol. 38: 903-907.
5. Shevach, E. M. 2006. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25: 195-201.
6. Wagner, J. E., A. D. Donnenberg, S. J. Noga, C. A. Cremo, I. K. Gao, H. J. Yin, G. B. Vogelsang, S. Rowley, R. Saral, and G. W. Santos. 1988. Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood 72: 1168-1176.
7. Drobyski, W. R., and D. Majewski. 1996. Treatment of donor mice with an αβ T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts. Blood 87: 5355-5369.
8. Cooke, K. R., W. Krenger, G. Hill, T. R. Martin, L. Kobzik, J. Brewer, R. Simmons, J. M. Crawford, M. R. van den Brink, and J. L. Ferrara. 1998. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood 92: 2571-2580.
9. Rutella, S., and R. M. Lemoli. 2004. Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol. Lett. 94: 11-26. (Pubitemid 38953707)
10. Delgado, M., D. Pozo, and D. Ganea. 2004. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56: 249-290. (Pubitemid 38720831)
11. Pozo, D., and M. Delgado, M. 2004. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J. 18: 1325-1334. (Pubitemid 39150347)
12. Gonzalez-Rey, E., A. Chorny, and M. Delgado. 2007. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat. Rev. Immunol. 7: 52-63. (Pubitemid 46020827)
13. Pozo, D., E. Gonzalez-Rey, A. Chorny, P. Anderson, N. Varela, and M. Delgado. 2007. Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides 28: 1833-1846. (Pubitemid 47361418)
14. Gonzalez-Rey, E., and M. Delgado. 2007. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol. Med. 13: 241-251. (Pubitemid 46836872)
15. + regulatory T cells in vivo. J. Leukocyte Biol. 78: 1327-1338.
16. Fernandez-Martin, A., E. Gonzalez-Rey, A. Chorny, D. Ganea, and M. Delgado. 2006. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 36: 318-326. (Pubitemid 43257454)
17. + T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum. 54: 864-876.
18. Delgado, M., and D. Ganea. 2001. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-κB-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J. Biol. Chem. 276: 369-380.
19. +FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-β dependent but does not confer a regulatory phenotype. Blood 110: 2983-2990.
20. + T lymphocytes. J. Immunol. 169: 6231-6235.
21. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198: 1875-1886.
22. Chorny, A., E. Gonzalez-Rey, A. Fernandez-Martin, D. Ganea, and M. Delgado. 2006. Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood 107: 3787-3794.
23. Schwartz, R. H. 1997. T cell clonal anergy. Curr. Opin. Immunol. 9: 351-357.
24. Boussiotis, V. A., Z. M. Chen, J. C. Zeller, W. J. Murphy, A. Berezovskaya, S. Narula, M. G. Roncarolo, and B. R. Blazar. 2001. Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-β-treated alloreactive T cells that do not induce graft-versus-host disease. Blood 97: 565-571.
25. Boussiotis, V. A., G. J. Freeman, P. A. Taylor, A. Berezovskaya, I. Grass, B. R. Blazar, and L. M. Nadler. 2000. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 6: 290-297.
26. - T cells. Blood 109: 244-252.
27. + regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 106: 3068-3073.
28. Lee, S. M., B. Gao, and D. Fang. 2008. FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1. Blood 111: 3599-3606.
29. + regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 110: 1550-1558.
30. + cells: a naturally occurring population of regulatory T cells. Blood 98: 2736-2744.
31. + regulatory T cells. J. Leukocyte Biol. 80: 145-151.
32. + regulatory T cells ex vivo. Blood 102: 2180-2186.
33. Jago, C. B., J. Yates, N. O. Camara, R. I. Lechler, and G. Lombardi. 2004. Differential expression of CTLA-4 among T cell subsets. Clin. Exp. Immunol. 136: 463-471.
34. + regulatory T cells. J. Immunol. 176: 3321-3329.
35. + lymphocytes in the marrow graft. Bone Marrow Transplant. 23: 443-450.
36. + T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J. Clin. Invest. 102: 473-482.
37. Appleman, L. J., A. Berezovskaya, I. Grass, and V. A. Boussiotis. 2000. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J. Immunol. 164: 144-151.
38. Nakayama, K. I., S. Hatakeyama, and K. Nakayama. 2001. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem. Biophys. Res. Commun. 282: 853-860.
39. Assoian, R. K. 2004. Stopping and going with p27kip1. Dev. Cell 6: 458-459.
40. Coqueret, O. 2003. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 13: 65-70.
41. Miller, J. P., N. Yeh, A. Vidal, and A. Koff. 2007. Interweaving the cell cycle machinery with cell differentiation. Cell Cycle 6: 2932-2938.
42. Vidal, A., and A. Koff. 2000. Cell-cycle inhibitors: three families united by a common cause. Gene 247: 1-15.
43. Gonzalez-Rey, E., and M. Delgado. 2007. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders? Trends Pharmacol. Sci. 28: 482-491. (Pubitemid 47368698)
44. Roncarolo, M. G., and M. Battaglia. 2007. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 7: 585-598.
45. Sakaguchi, S. 2008. Regulatory T cells in the past and for the future. Eur. J. Immunol. 38: 901-937.
46. Sakaguchi, S., and F. Powrie. 2007. Emerging challenges in regulatory T cell function and biology. Science 317: 627-629.
47. + regulatory T lymphocytes. Nat. Med. 14: 88-92.
48. - subpopulations. J. Immunol. 165: 3105-3110.
49. - T cells. J. Clin. Invest. 112: 1437-1443.
50. + T cells. J. Exp. Med. 184: 19-29.
51. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737-742.
52. Shevach, E. M., D. Q. Tran, T. S. Davidson, and J. Anderson. 2008. The critical contribution of TGF-β to the induction of Foxp3 expression and regulatory T cell function. Eur. J. Immunol. 38: 915-917.
53. + Treg. Eur. J. Immunol. 38: 912-915.
54. Kawada, M., S. Yamagoe, Y. Murakami, K. Suzuki, S. Mizuno, and Y. Uehara. 1997. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15: 629-637.
55. Liang, J., and J. M. Slingerland. 2003. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2: 339-345.
56. Grader-Beck, T., A. A. van Puijenbroek, L. M. Nadler, and V. A. Boussiotis. 2003. cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression. Blood 101: 998-1006.
57. Heijink, I. H., H. F. Kauffman, D. S. Postma, J. G. de Monchy, and E. Vellenga. 2003. Sensitivity of IL-5 production to the cAMP-dependent pathway in human T cells is reduced by exogenous IL-2 in a phosphoinositide 3-kinase-dependent way. Eur. J. Immunol. 33: 2206-2215.
58. Ramstad, C., V. Sundvold, H. K. Johansen, and T. Lea. 2000. cAMP-dependent protein kinase (PKA) inhibits T cell activation by phosphorylating Ser-43 of raf-1 in the MAPK/ERK pathway. Cell. Signal. 12: 557-563.
59. kip1 and cyclin D3 to suppress proliferation of leukemic T cell lines. J. Biol. Chem. 276: 33854-33860.
60. + T cells. J. Immunol. 175: 1483-1490.
61. + suppressor T cells in vivo. Nat. Immunol. 3: 33-41.
62. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193: 1295-1302.